Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. - Wikidata - wikimedia - TriplyDB

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

http://www.wikidata.org/entity/Q42158416

about

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Diagnosis and classification of hematologic malignancies on the basis of genetics.The genomic landscape of pediatric myelodysplastic syndromes.Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome - not because we can, but because we should.Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.Ribosomopathies: There's strength in numbers.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome.Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways.Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.Inherited bone marrow failure syndromes: considerations pre- and posttransplant.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.Clonality in context: hematopoietic clones in their marrow environment.Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53.Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.The genetic basis and cell of origin of mixed phenotype acute leukaemia

P2860

Q38606945-695D3C53-3080-4611-8770-9682DF0B42A7 Q38627087-981BAED5-107A-409F-8DFE-D8B6CE9D4EEC Q39092515-550668CB-3FF8-4485-B406-BC4A26C6CDA8 Q39363409-ACE4004A-6AFB-4F58-82CD-91C9111EF774 Q47099740-EE5E64EC-67B1-40BD-BA9F-FA4637593507 Q47134198-C00EED94-16AE-4491-A2A6-20BFD9C6AB7F Q47145985-9DF46DCF-E5BD-48E6-869A-F167761AB6CD Q47158332-8EA9E3EA-3123-4703-B1FD-D77F8FC4A682 Q47159841-45748D80-B16F-45C6-8DA6-C0A2CA790892 Q47447659-B96A8004-F6F2-405C-BDC6-DEBB7CEA1BB4 Q47548041-2BACD502-0042-41D3-8F51-37A272A43BF6 Q48108171-F9478431-B68C-4269-9637-BB54D32CB690 Q48123200-1EEECB0F-6F7B-4B2C-95A2-134EA4208A97 Q48127990-A7D0067D-55F8-4E3C-B173-9F7292DF45EA Q49165108-8CE25192-0304-4C60-AA6C-3F4E7D91190C Q49200018-D7F10FA2-0328-4B4B-90A7-BFF84D0B12A4 Q49789092-4BBED9BB-741F-4DC0-AAB7-0BE7ADA7E1F8 Q49976405-BBA376DB-B664-43C0-B30C-668CBD5AD323 Q50091222-A044CF12-C842-4BF6-A8D2-16B87589DB51 Q50209900-ED3B848F-75E6-48E7-9482-F2950EB02B33 Q51415663-7F52291B-5083-4CB6-9547-441BE1077814 Q52728106-002BC95B-4CCF-48E4-8702-B626685E76B2 Q53820609-525F433C-D4FC-464C-A0F3-703BC3645544 Q55191948-78CF771F-9C31-4FAE-8888-640B9B883B13 Q55251895-34FD486F-B50E-4E8B-9854-76F5C6DB1AE5 Q55364989-B63A194E-1064-4A02-8728-E1E0143ADF49 Q57158107-ECA926B1-4FFE-4F17-9C14-A33FDC1D4D23

P2860

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

http://www.wikidata.org/entity/Q42158416

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@en

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@nl

type

label

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@en

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@nl

prefLabel

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@en

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@nl

P1433

Q42158416-F1538164-6281-404B-AB09-E6BB4F9FE327

P1476

Q42158416-6F5E3609-5F83-4503-8A17-325AF03CEF50

P2093

Q42158416-209EAE66-E051-4CD3-9949-D5B9939EA534

Q42158416-2214FD5A-F694-4BC7-85D5-CE2413F9758C

Q42158416-33B677C6-81AE-46A7-BACA-A97163F03FCC

Q42158416-3CBC48FC-361B-4553-B142-155161EF088B

Q42158416-475A1058-997B-410F-95E2-6F9C78C01105

Q42158416-486E1759-9F34-4CC0-BAFA-2A2AD189245D

Q42158416-5DB4C06A-7246-4102-A261-D5BA41A49BF6

Q42158416-66867A13-30D1-4371-AF42-DAF00B9F81DC

Q42158416-A5AEA27C-9389-45E2-BF92-A3D059F7BFAD

Q42158416-A8FA0E7B-A9E3-47AD-904B-70F633458409

P2860

Q42158416-041D9A30-9887-4D3B-B767-ACC1BE209C34

Q42158416-0F14008D-9161-4360-8917-97E200E2B604

Q42158416-14941DD8-8509-4DE3-9BA9-D212595A2E7E

Q42158416-1F0E4C13-C050-462E-A7B3-AE726A8FAACD

Q42158416-30D88DCA-49CB-406A-B755-25CBE2B28A1E

Q42158416-33E20E78-E3EB-47D7-9918-52CD693B88FD

Q42158416-41677A64-5BE8-4E49-8DFA-10BEBA15EB23

Q42158416-495CD0A4-ED43-4A91-89AF-979529AA177C

Q42158416-5DD2BB2E-DDB4-41CE-89A8-B7AA647AA620

Q42158416-670213A7-9AD0-4F20-BD1B-995183B19B81

P304

Q42158416-9B432C0B-BF42-4E8F-8688-58239E1BF67B

P31

Q42158416-2E833D54-9BA8-41EE-AAC4-0F8501CEB77C

P356

Q42158416-21F4FE01-7FEA-49EF-97D4-EAAA94708309

P407

Q42158416-4AD4134D-71C6-44EE-AC22-4697BE148F41

P433

Q42158416-01DF5CF2-84EA-41F5-90FD-C1667D8AC92C

P478

Q42158416-7578C3EC-5F7F-405B-B1F7-40F25AD43579

P50

Q42158416-78F24F64-1D25-4080-BFD7-AF674FF1B48F

P577

Q42158416-404AE456-1016-4CF8-8FB2-8A4B953BA876

P698

Q42158416-0EBB3C62-2475-4270-9BB4-EF6EA1C8B9C6

P932

Q42158416-BD284264-11C6-4175-BC7A-061505F36A44

P356

P1433

The New England Journal of Medicine

P1476

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

@en

P2093

Benjamin L Ebert

http://www.w3.org/2001/XMLSchema#string

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Katharina Fleischhauer

http://www.w3.org/2001/XMLSchema#string

Katharine Hsu

http://www.w3.org/2001/XMLSchema#string

Michael D Haagenson

http://www.w3.org/2001/XMLSchema#string

Michael R Verneris

http://www.w3.org/2001/XMLSchema#string

Peter V Grauman

http://www.w3.org/2001/XMLSchema#string

R Coleman Lindsley

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Clinical effect of point mutations in myelodysplastic syndromes

Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome.

Genetic predisposition syndromes: when should they be considered in the work-up of MDS?

Variable clinical presentation of Shwachman-Diamond syndrome: update from the North American Shwachman-Diamond Syndrome Registry.

Mutations in SBDS are associated with Shwachman-Diamond syndrome.

P304

536-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1611604

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28177873

http://www.w3.org/2001/XMLSchema#string

P932

5438571

http://www.w3.org/2001/XMLSchema#string